Literature DB >> 17023827

A proposed score for predicting severe infection complications in children with chemotherapy-induced febrile neutropenia.

Patrícia Imperatriz Porto Rondinelli1, Karina de Cássia Braga Ribeiro, Beatriz de Camargo.   

Abstract

BACKGROUND: Febrile neutropenia (FN) is one of most common complications in patients with cancer during chemotherapy. Identifying factors associated with severe infectious complications (SICs) at time of admission for fever and neutropenia is necessary for better treatment. PROCEDURE: We revised all medical charts of patients under 18 years old who developed a first episode of FN present from January 2000 to December 2003. Criteria for a SIC were defined. These included the presence of bacteremia or fungemia, sepsis, septic shock, and/or death from infection. To identify risk factors SIC was associated with the first FN episode.
RESULTS: Factors identified in univariate analysis were female sex, age less than 5 years old, acute myeloid leukemia, baseline disease activity, use of central venous catheter, hemoglobin level < 7 g/dL, leukocytes count < 500 cells/mm(3), granulocytes count < 500 cells/mm(3), monocytes count < 100 cells/mm(3), platelets < 20,000, and body temperature > 38.5 degrees C, a chemotherapy interval < 7 days, presence of mucositis, pneumonia, absence of upper respiratory tract infection, or the presence of any clinical focus on first physical examination. In multivariate analysis the variables that remained as independent predictive risk factors for SIC were age less than 5 years, use of central venous catheter, body temperature > 38.5 degrees C, hemoglobin level < 7 g/dL, any clinical focus of infection on first examination and absence of upper respiratory tract infection. The FN population was than divided among 3 different risk groups as follows: group 1 (low risk), group 2 (intermediate risk), with a 13 (4.4 to 38.3)-fold risk for SIC; and group 3 (high risk) with a 50 (16.4 to 149.2)-fold risk for SIC.
CONCLUSIONS: This study suggests that patients with FN can be stratified for risk of SIC using clinical parameters at hospital admission.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17023827     DOI: 10.1097/01.mph.0000212996.94929.0b

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  22 in total

Review 1.  Outpatient and oral antibiotic management of low-risk febrile neutropenia are effective in children--a systematic review of prospective trials.

Authors:  A Manji; J Beyene; L L Dupuis; R Phillips; T Lehrnbecher; L Sung
Journal:  Support Care Cancer       Date:  2012-03-09       Impact factor: 3.603

2.  Febrile neutropenia: transition towards a risk-directed approach.

Authors:  P Anoop; M A Anjay
Journal:  Arch Dis Child       Date:  2007-05       Impact factor: 3.791

3.  Impact of respiratory viral panel testing on length of stay in pediatric cancer patients admitted with fever and neutropenia.

Authors:  Kaitlin Shinn; Martha Wetzel; Nicholas P DeGroote; Frank Keller; Michael Briones; James Felker; Sharon Castellino; Tamara P Miller
Journal:  Pediatr Blood Cancer       Date:  2020-09-02       Impact factor: 3.167

4.  Can complications in febrile neutropenia be predicted? Report from a developing country.

Authors:  Sapna Oberoi; Anirban Das; Amita Trehan; Pallab Ray; Deepak Bansal
Journal:  Support Care Cancer       Date:  2017-06-11       Impact factor: 3.603

5.  Development and validation of a prediction model for diagnosing blood stream infections in febrile, non-neutropenic children with cancer.

Authors:  Adam J Esbenshade; M Cecilia Di Pentima; Zhiguo Zhao; Ayumi Shintani; Jennifer C Esbenshade; Monique E Simpson; Kathleen C Montgomery; Robert B Lindell; Haerin Lee; Ato Wallace; Kelly L Garcia; Karel G M Moons; Debra L Friedman
Journal:  Pediatr Blood Cancer       Date:  2014-10-18       Impact factor: 3.167

6.  Etiology and clinical course of febrile neutropenia in children with cancer.

Authors:  Hana Hakim; Patricia M Flynn; Katherine M Knapp; Deo Kumar Srivastava; Aditya H Gaur
Journal:  J Pediatr Hematol Oncol       Date:  2009-09       Impact factor: 1.289

7.  Evaluation of a fever-management algorithm in a pediatric cancer center in a low-resource setting.

Authors:  Sheena Mukkada; Cristel Kate Smith; Delta Aguilar; April Sykes; Li Tang; Mae Dolendo; Miguela A Caniza
Journal:  Pediatr Blood Cancer       Date:  2017-09-12       Impact factor: 3.167

8.  Infectious Morbidity in Pediatric Patients Receiving Neoadjuvant Chemotherapy for Sarcoma.

Authors:  Denise Willmer; Stefan K Zöllner; Frieder Schaumburg; Heribert Jürgens; Thomas Lehrnbecher; Andreas H Groll
Journal:  Cancers (Basel)       Date:  2021-04-21       Impact factor: 6.639

Review 9.  Systematic review and meta-analysis of the discriminatory performance of risk prediction rules in febrile neutropaenic episodes in children and young people.

Authors:  Bob Phillips; Ros Wade; Lesley A Stewart; Alex J Sutton
Journal:  Eur J Cancer       Date:  2010-11       Impact factor: 9.162

10.  Outpatient management of febrile neutropenia in children with cancer.

Authors:  Ottavio Ziino; Fabio Tucci; Mario Renato Rossi
Journal:  Pediatr Rep       Date:  2011-02-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.